United States Cholesterol-Lowering Drugs Market Report 2017

United States Cholesterol-Lowering Drugs Market Report 2017

1 Cholesterol-Lowering Drugs Overview

1.1 Product Overview and Scope of Cholesterol-Lowering Drugs

1.2 Classification of Cholesterol-Lowering Drugs by Product Category

1.2.1 United States Cholesterol-Lowering Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)

1.2.2 United States Cholesterol-Lowering Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016

1.2.3 Statins

1.2.4 Cholesterol Absorption Inhibitors

1.2.5 Fibrates

1.2.6 PCSK9 Inhibitors

1.3 United States Cholesterol-Lowering Drugs Market by Application/End Users

1.3.1 United States Cholesterol-Lowering Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)

1.3.2 Hospital

1.3.3 Household

1.3.4 Other

1.4 United States Cholesterol-Lowering Drugs Market by Region

1.4.1 United States Cholesterol-Lowering Drugs Market Size (Value) Comparison by Region (2012-2022)

1.4.2 The West Cholesterol-Lowering Drugs Status and Prospect (2012-2022)

1.4.3 Southwest Cholesterol-Lowering Drugs Status and Prospect (2012-2022)

1.4.4 The Middle Atlantic Cholesterol-Lowering Drugs Status and Prospect (2012-2022)

1.4.5 New England Cholesterol-Lowering Drugs Status and Prospect (2012-2022)

1.4.6 The South Cholesterol-Lowering Drugs Status and Prospect (2012-2022)

1.4.7 The Midwest Cholesterol-Lowering Drugs Status and Prospect (2012-2022)

1.5 United States Market Size (Value and Volume) of Cholesterol-Lowering Drugs (2012-2022)

1.5.1 United States Cholesterol-Lowering Drugs Sales and Growth Rate (2012-2022)

1.5.2 United States Cholesterol-Lowering Drugs Revenue and Growth Rate (2012-2022)

2 United States Cholesterol-Lowering Drugs Market Competition by Players/Suppliers

2.1 United States Cholesterol-Lowering Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)

2.2 United States Cholesterol-Lowering Drugs Revenue and Share by Players/Suppliers (2012-2017)

2.3 United States Cholesterol-Lowering Drugs Average Price by Players/Suppliers (2012-2017)

2.4 United States Cholesterol-Lowering Drugs Market Competitive Situation and Trends

2.4.1 United States Cholesterol-Lowering Drugs Market Concentration Rate

2.4.2 United States Cholesterol-Lowering Drugs Market Share of Top 3 and Top 5 Players/Suppliers

2.4.3 Mergers & Acquisitions, Expansion in United States Market

2.5 United States Players/Suppliers Cholesterol-Lowering Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Cholesterol-Lowering Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)

3.1 United States Cholesterol-Lowering Drugs Sales and Market Share by Region (2012-2017)

3.2 United States Cholesterol-Lowering Drugs Revenue and Market Share by Region (2012-2017)

3.3 United States Cholesterol-Lowering Drugs Price by Region (2012-2017)

4 United States Cholesterol-Lowering Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)

4.1 United States Cholesterol-Lowering Drugs Sales and Market Share by Type (Product Category) (2012-2017)

4.2 United States Cholesterol-Lowering Drugs Revenue and Market Share by Type (2012-2017)

4.3 United States Cholesterol-Lowering Drugs Price by Type (2012-2017)

4.4 United States Cholesterol-Lowering Drugs Sales Growth Rate by Type (2012-2017)

5 United States Cholesterol-Lowering Drugs Sales (Volume) by Application (2012-2017)

5.1 United States Cholesterol-Lowering Drugs Sales and Market Share by Application (2012-2017)

5.2 United States Cholesterol-Lowering Drugs Sales Growth Rate by Application (2012-2017)

5.3 Market Drivers and Opportunities

6 United States Cholesterol-Lowering Drugs Players/Suppliers Profiles and Sales Data

6.1 AstraZeneca

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Cholesterol-Lowering Drugs Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 AstraZeneca Cholesterol-Lowering Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 Merck

6.2.2 Cholesterol-Lowering Drugs Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Merck Cholesterol-Lowering Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 Pfizer

6.3.2 Cholesterol-Lowering Drugs Product Category, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Pfizer Cholesterol-Lowering Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

6.4 Kowa

6.4.2 Cholesterol-Lowering Drugs Product Category, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Kowa Cholesterol-Lowering Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

6.5 Daiichi Sankyo

6.5.2 Cholesterol-Lowering Drugs Product Category, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 Daiichi Sankyo Cholesterol-Lowering Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Main Business/Business Overview

6.6 AbbVie

6.6.2 Cholesterol-Lowering Drugs Product Category, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 AbbVie Cholesterol-Lowering Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Main Business/Business Overview

6.7 Novartis

6.7.2 Cholesterol-Lowering Drugs Product Category, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 Novartis Cholesterol-Lowering Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.7.4 Main Business/Business Overview

6.8 Sanofi

6.8.2 Cholesterol-Lowering Drugs Product Category, Application and Specification

6.8.2.1 Product A

6.8.2.2 Product B

6.8.3 Sanofi Cholesterol-Lowering Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.8.4 Main Business/Business Overview

6.9 Amgen

6.9.2 Cholesterol-Lowering Drugs Product Category, Application and Specification

6.9.2.1 Product A

6.9.2.2 Product B

6.9.3 Amgen Cholesterol-Lowering Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.9.4 Main Business/Business Overview

6.10 Bristol-Myers Squibb

6.10.2 Cholesterol-Lowering Drugs Product Category, Application and Specification

6.10.2.1 Product A

6.10.2.2 Product B

6.10.3 Bristol-Myers Squibb Cholesterol-Lowering Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.10.4 Main Business/Business Overview

7 Cholesterol-Lowering Drugs Manufacturing Cost Analysis

7.1 Cholesterol-Lowering Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Cholesterol-Lowering Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers

8.1 Cholesterol-Lowering Drugs Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Cholesterol-Lowering Drugs Major Manufacturers in 2016

8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List

10 Market Effect Factors Analysis

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

11 United States Cholesterol-Lowering Drugs Market Size (Value and Volume) Forecast (2017-2022)

11.1 United States Cholesterol-Lowering Drugs Sales Volume, Revenue Forecast (2017-2022)

11.2 United States Cholesterol-Lowering Drugs Sales Volume Forecast by Type (2017-2022)

11.3 United States Cholesterol-Lowering Drugs Sales Volume Forecast by Application (2017-2022)

11.4 United States Cholesterol-Lowering Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

Figure Product Picture of Cholesterol-Lowering Drugs

Figure United States Cholesterol-Lowering Drugs Market Size (K Pcs) by Type (2012-2022)

Figure United States Cholesterol-Lowering Drugs Sales Volume Market Share by Type (Product Category) in 2016

Figure Statins Product Picture

Figure Cholesterol Absorption Inhibitors Product Picture

Figure Fibrates Product Picture

Figure PCSK9 Inhibitors Product Picture

Figure United States Cholesterol-Lowering Drugs Market Size (K Pcs) by Application (2012-2022)

Figure United States Sales Market Share of Cholesterol-Lowering Drugs by Application in 2016

Figure Hospital Examples

Table Key Downstream Customer in Hospital

Figure Household Examples

Table Key Downstream Customer in Household

Figure Other Examples

Table Key Downstream Customer in Other

Figure United States Cholesterol-Lowering Drugs Market Size (Million USD) by Region (2012-2022)

Figure The West Cholesterol-Lowering Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure Southwest Cholesterol-Lowering Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The Middle Atlantic Cholesterol-Lowering Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure New England Cholesterol-Lowering Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The South of US Cholesterol-Lowering Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The Midwest Cholesterol-Lowering Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure United States Cholesterol-Lowering Drugs Sales (K Pcs) and Growth Rate (2012-2022)

Figure United States Cholesterol-Lowering Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure United States Cholesterol-Lowering Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)

Table United States Cholesterol-Lowering Drugs Sales (K Pcs) of Key Players/Suppliers (2012-2017)

Table United States Cholesterol-Lowering Drugs Sales Share by Players/Suppliers (2012-2017)

Figure 2016 United States Cholesterol-Lowering Drugs Sales Share by Players/Suppliers

Figure 2017 United States Cholesterol-Lowering Drugs Sales Share by Players/Suppliers

Figure United States Cholesterol-Lowering Drugs Market Major Players Product Revenue (Million USD) (2012-2017)

Table United States Cholesterol-Lowering Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)

Table United States Cholesterol-Lowering Drugs Revenue Share by Players/Suppliers (2012-2017)

Figure 2016 United States Cholesterol-Lowering Drugs Revenue Share by Players/Suppliers

Figure 2017 United States Cholesterol-Lowering Drugs Revenue Share by Players/Suppliers

Table United States Market Cholesterol-Lowering Drugs Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)

Figure United States Market Cholesterol-Lowering Drugs Average Price (USD/Pcs) of Key Players/Suppliers in 2016

Figure United States Cholesterol-Lowering Drugs Market Share of Top 3 Players/Suppliers

Figure United States Cholesterol-Lowering Drugs Market Share of Top 5 Players/Suppliers

Table United States Players/Suppliers Cholesterol-Lowering Drugs Manufacturing Base Distribution and Sales Area

Table United States Players/Suppliers Cholesterol-Lowering Drugs Product Category

Table United States Cholesterol-Lowering Drugs Sales (K Pcs) by Region (2012-2017)

Table United States Cholesterol-Lowering Drugs Sales Share by Region (2012-2017)

Figure United States Cholesterol-Lowering Drugs Sales Share by Region (2012-2017)

Figure United States Cholesterol-Lowering Drugs Sales Market Share by Region in 2016

Table United States Cholesterol-Lowering Drugs Revenue (Million USD) and Market Share by Region (2012-2017)

Table United States Cholesterol-Lowering Drugs Revenue Share by Region (2012-2017)

Figure United States Cholesterol-Lowering Drugs Revenue Market Share by Region (2012-2017)

Figure United States Cholesterol-Lowering Drugs Revenue Market Share by Region in 2016

Table United States Cholesterol-Lowering Drugs Price (USD/Pcs) by Region (2012-2017)

Table United States Cholesterol-Lowering Drugs Sales (K Pcs) by Type (2012-2017)

Table United States Cholesterol-Lowering Drugs Sales Share by Type (2012-2017)

Figure United States Cholesterol-Lowering Drugs Sales Share by Type (2012-2017)

Figure United States Cholesterol-Lowering Drugs Sales Market Share by Type in 2016

Table United States Cholesterol-Lowering Drugs Revenue (Million USD) and Market Share by Type (2012-2017)

Table United States Cholesterol-Lowering Drugs Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Cholesterol-Lowering Drugs by Type (2012-2017)

Figure Revenue Market Share of Cholesterol-Lowering Drugs by Type in 2016

Table United States Cholesterol-Lowering Drugs Price (USD/Pcs) by Types (2012-2017)

Figure United States Cholesterol-Lowering Drugs Sales Growth Rate by Type (2012-2017)

Table United States Cholesterol-Lowering Drugs Sales (K Pcs) by Application (2012-2017)

Table United States Cholesterol-Lowering Drugs Sales Market Share by Application (2012-2017)

Figure United States Cholesterol-Lowering Drugs Sales Market Share by Application (2012-2017)

Figure United States Cholesterol-Lowering Drugs Sales Market Share by Application in 2016

Table United States Cholesterol-Lowering Drugs Sales Growth Rate by Application (2012-2017)

Figure United States Cholesterol-Lowering Drugs Sales Growth Rate by Application (2012-2017)

Table AstraZeneca Basic Information List

Table AstraZeneca Cholesterol-Lowering Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure AstraZeneca Cholesterol-Lowering Drugs Sales Growth Rate (2012-2017)

Figure AstraZeneca Cholesterol-Lowering Drugs Sales Market Share in United States (2012-2017)

Figure AstraZeneca Cholesterol-Lowering Drugs Revenue Market Share in United States (2012-2017)

Table Merck Basic Information List

Table Merck Cholesterol-Lowering Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Merck Cholesterol-Lowering Drugs Sales Growth Rate (2012-2017)

Figure Merck Cholesterol-Lowering Drugs Sales Market Share in United States (2012-2017)

Figure Merck Cholesterol-Lowering Drugs Revenue Market Share in United States (2012-2017)

Table Pfizer Basic Information List

Table Pfizer Cholesterol-Lowering Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Pfizer Cholesterol-Lowering Drugs Sales Growth Rate (2012-2017)

Figure Pfizer Cholesterol-Lowering Drugs Sales Market Share in United States (2012-2017)

Figure Pfizer Cholesterol-Lowering Drugs Revenue Market Share in United States (2012-2017)

Table Kowa Basic Information List

Table Kowa Cholesterol-Lowering Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Kowa Cholesterol-Lowering Drugs Sales Growth Rate (2012-2017)

Figure Kowa Cholesterol-Lowering Drugs Sales Market Share in United States (2012-2017)

Figure Kowa Cholesterol-Lowering Drugs Revenue Market Share in United States (2012-2017)

Table Daiichi Sankyo Basic Information List

Table Daiichi Sankyo Cholesterol-Lowering Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Daiichi Sankyo Cholesterol-Lowering Drugs Sales Growth Rate (2012-2017)

Figure Daiichi Sankyo Cholesterol-Lowering Drugs Sales Market Share in United States (2012-2017)

Figure Daiichi Sankyo Cholesterol-Lowering Drugs Revenue Market Share in United States (2012-2017)

Table AbbVie Basic Information List

Table AbbVie Cholesterol-Lowering Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure AbbVie Cholesterol-Lowering Drugs Sales Growth Rate (2012-2017)

Figure AbbVie Cholesterol-Lowering Drugs Sales Market Share in United States (2012-2017)

Figure AbbVie Cholesterol-Lowering Drugs Revenue Market Share in United States (2012-2017)

Table Novartis Basic Information List

Table Novartis Cholesterol-Lowering Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Novartis Cholesterol-Lowering Drugs Sales Growth Rate (2012-2017)

Figure Novartis Cholesterol-Lowering Drugs Sales Market Share in United States (2012-2017)

Figure Novartis Cholesterol-Lowering Drugs Revenue Market Share in United States (2012-2017)

Table Sanofi Basic Information List

Table Sanofi Cholesterol-Lowering Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Sanofi Cholesterol-Lowering Drugs Sales Growth Rate (2012-2017)

Figure Sanofi Cholesterol-Lowering Drugs Sales Market Share in United States (2012-2017)

Figure Sanofi Cholesterol-Lowering Drugs Revenue Market Share in United States (2012-2017)

Table Amgen Basic Information List

Table Amgen Cholesterol-Lowering Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Amgen Cholesterol-Lowering Drugs Sales Growth Rate (2012-2017)

Figure Amgen Cholesterol-Lowering Drugs Sales Market Share in United States (2012-2017)

Figure Amgen Cholesterol-Lowering Drugs Revenue Market Share in United States (2012-2017)

Table Bristol-Myers Squibb Basic Information List

Table Bristol-Myers Squibb Cholesterol-Lowering Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Bristol-Myers Squibb Cholesterol-Lowering Drugs Sales Growth Rate (2012-2017)

Figure Bristol-Myers Squibb Cholesterol-Lowering Drugs Sales Market Share in United States (2012-2017)

Figure Bristol-Myers Squibb Cholesterol-Lowering Drugs Revenue Market Share in United States (2012-2017)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Cholesterol-Lowering Drugs

Figure Manufacturing Process Analysis of Cholesterol-Lowering Drugs

Figure Cholesterol-Lowering Drugs Industrial Chain Analysis

Table Raw Materials Sources of Cholesterol-Lowering Drugs Major Players/Suppliers in 2016

Table Major Buyers of Cholesterol-Lowering Drugs

Table Distributors/Traders List

Figure United States Cholesterol-Lowering Drugs Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)

Figure United States Cholesterol-Lowering Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure United States Cholesterol-Lowering Drugs Price (USD/Pcs) Trend Forecast (2017-2022)

Table United States Cholesterol-Lowering Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)

Figure United States Cholesterol-Lowering Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)

Figure United States Cholesterol-Lowering Drugs Sales Volume (K Pcs) Forecast by Type in 2022

Table United States Cholesterol-Lowering Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)

Figure United States Cholesterol-Lowering Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)

Figure United States Cholesterol-Lowering Drugs Sales Volume (K Pcs) Forecast by Application in 2022

Table United States Cholesterol-Lowering Drugs Sales Volume (K Pcs) Forecast by Region (2017-2022)

Table United States Cholesterol-Lowering Drugs Sales Volume Share Forecast by Region (2017-2022)

Figure United States Cholesterol-Lowering Drugs Sales Volume Share Forecast by Region (2017-2022)

Figure United States Cholesterol-Lowering Drugs Sales Volume Share Forecast by Region in 2022

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources